With a major regulatory revision to be in effect later in 2026, the European regulatory landscape governing pharmaceutical data and digital systems is evolving. While these rules originate from manufacturing oversight frameworks, their implications extend far beyond production environments. In this second article of our series on the EU GMP Guidelines revisions, we look at the implications for clinical development.
According to the European Commission “The revision of GMP Annex 11 and Chapter 4, along with the introduction of a dedicated Annex 22 on Artificial Intelligence aim at supporting innovation in the manufacturing of medicines and ensuring regulatory harmonisation.” 1
For the pharma industry as a whole, including clinical development teams, the message is clear: regulators are raising the bar for how pharmaceutical organizations should manage digital systems, data integrity, and advanced technologies such as artificial intelligence.
A shift toward lifecycle governance of digital systems
The upcoming revision of Annex 11 introduces a stronger emphasis on the governance of computerized systems. Pharmaceutical organizations are expected to demonstrate that their digital tools supporting regulated activities are designed, implemented, and maintained with appropriate controls throughout their entire lifecycle.
This includes more stringent expectations around:
- traceability of data and system actions
- management of user access and identity
- monitoring of system performance over time
- regular review of system reliability and security
In practice, these expectations increasingly apply to the platforms used across clinical development activities, including systems that support trial oversight, safety committees, or independent review processes. For clinical leaders, this means that digital tools must be able to demonstrate not only operational efficiency but also strong governance and accountability.
Data integrity becomes a strategic priority
Another major theme of the upcoming regulatory update is data integrity (revised Chapter 4). Regulators are underlining the principle that data must remain complete, reliable, and traceable throughout its entire lifecycle.
This extends beyond traditional document management. The updated approach reflects the reality that pharmaceutical data now exists in many forms, including digital records, automated system outputs, and complex datasets generated through analytics platforms.
Organizations will therefore need to ensure that their digital systems provide:
- transparent audit trails
- secure data handling processes
- clear documentation of data origin and modification
- controlled archiving and retrieval mechanisms
For clinical development programs, where multiple stakeholders interact with sensitive data, these requirements highlight the importance of selecting digital platforms capable of ensuring traceability and readability across all documents formats.
Artificial intelligence enters the regulatory framework
Perhaps the most notable development is the introduction of the new Annex 22, a dedicated framework addressing the use of artificial intelligence and machine learning systems used in pharmaceutical operations.
As AI-driven tools become increasingly common in areas such as predictive analytics, safety monitoring, and operational optimization, regulators are defining expectations for how these technologies should be controlled.
The new framework emphasizes several key principles:
- clearly defined intended use for AI models
- documented evaluation of model performance
- transparency around training data and decision logic
- ongoing monitoring to ensure models continue to perform as expected
Human oversight remains essential. Organizations must ensure that qualified experts remain responsible for reviewing AI-supported outputs and making critical decisions.
Implications for clinical development teams
Although these requirements are initially focused on regulated manufacturing environments, their influence will inevitably extend into digital ecosystems used throughout drug development.
Consequently, the systems that support clinical development programs must be able to demonstrate:
- strong governance frameworks
- reliable data management
- transparency in automated processes
- readiness for regulatory scrutiny
Digital platforms are no longer viewed simply as operational tools. They are becoming regulated components of the pharmaceutical quality ecosystem.
Organizations that anticipate these expectations today will be better positioned to navigate the increasingly “data-driven” regulatory environment of the coming years.
What comes next
This concludes the second article of our series on the forthcoming EU regulations updates of GMP Guidelines Chapter 4 and Annex 11, and New Annex 22. As digital technologies continue to reshape the industry, expectations around system accountability, data governance and AI transparency will continue to grow stronger. Our last article will focus on the new expectations regarding the use of AI and what the implications are for organisations, clinical development teams and the digital platforms themselves.
Would you like to find out how Ethical’s platforms for managing independent expert committees support not only operational efficiency but also strong governance and accountability as required in the forthcoming European regulatory updates? Feel free to contact us through the form below. We’d be delighted to introduce you to our software solutions.
